Gene therapy for Wiskott-Aldrich Syndrome—Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis

Christian Joerg Braun1, Maximilian Witzel1, Anna Paruzynski2,1, Kaan Boztug3,1, Christof von Kalle2, Manfred Schmidt3, and Christoph Klein1,*
1Dr. von Hauner Children’s Hospital; Ludwig Maximilians University Munich; Munich, Germany; 2Department of Translational Oncology; National Center for Tumor Diseases and German Cancer Research Center; Heidelberg, Germany; 3Department of Pediatric Hematology/Oncology; Hannover Medical School; Hannover, Germany

Wiskott-Aldrich-Syndrome (WAS) is a rare X-linked recessive disease caused by mutations of the WAS gene. It is characterized by immunodeficiency, autoimmunity, low numbers of small platelets (microthrombocytopenia) and a high risk of cancer, especially B cell lymphoma and leukemia.

Haematopoietic stem cell transplantation (HSCT) is considered the standard curative therapy option – but the procedure can have major side effects and is limited by donor availability. Gene therapy with gammaretroviral vectors is able to overcome some of these shortcomings and lead to (at least a partial and temporary) functional immune system reconstitution, but it is associated with the development of leukemia after viral integration and oncogene transactivation. The high rate of integration-associated oncogene activation underlines the necessity for the development and application of safer genome-engineering technologies with similar efficacy and reduced toxicity.

Gene Therapy as an Alternative Treatment for WAS Leads to Molecular and Functional Correction of Disease

Over the last decades, gammaretrovirus-based HSC gene therapy (GT) has emerged as an alternative therapeutic strategy for the treatment of hereditary diseases of the immune system (reviewed in8,9). Patients suffering from chronic granulomatous disease (CGD),10 adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID),11,12 and X-linked SCID13-15 experienced clinical improvements and at least partial or temporary correction of immune cell functions. However, severe clinical
side-effects, including acute leukemia secondary to insertional mutagenesis and activation of proto-oncogenes, have raised concerns about therapeutic safety.16-22

Ten patients suffering from WAS were treated with haematopoietic GT using classical gammaretroviral vectors between 2006 and 2009.23,24 Briefly, after stimulation with recombinant human granulocyte colony-stimulating factor (rhG-CSF) and/or plerixafor, peripheral mononuclear cells were harvested and transduced with a replication-incompetent gammaretroviral vector that expressed a healthy copy of WAS driven by a murine stem cell virus-derived long terminal repeat (LTR) sequence. Patients were conditioned using myeloablative busulfan therapy (8mg/kg) prior to reinfusion of transduced cells. After GT, we were able to observe a strong and sustained expression of WASP in peripheral nuclear blood cells and in platelets, along with an overall reconstitution of lymphocyte function. Patients also showed remarkable clinical improvements with partial to complete resolution of autoimmunity, bleeding diathesis and susceptibility for infections.

A few specific lessons of this study are outlined below:

Age at GT Might Influence Speed of Haematopoietic Reconstitution

While most of our patients were young children at the time of treatment and mostly reconstituted fast after GT, one patient at the age of 14 at the time of GT experienced only a slow reconstitution of his immune system. A similar observation had already been described in a GT trial for X-SCID,25 thus pointing to a potentially slower overall reconstitution in older patients.

Gammaretroviral Gene Therapy Vector Integration Favors Certain Genomic Regions

Retroviral insertion site (IS) analysis using standard and nonrestrictive (nr) linear amplification-mediated polymerase chain reaction (LAM-PCR)26 revealed more than 140,000 unambiguous ISs with an initially highly polyclonal repopulation of the haematopoietic system. A comprehensive analysis of IS patterns demonstrated a typical gammaretroviral insertion pattern with integrations accumulating at transcription start sites (TSS) of gene-coding regions. The majority of most frequently affected genes had previously been described as proto-oncogenes (including MECOM27 and LMO228).

Insertional Mutagenesis Leads to Gene Activation and the Development of Haematopoietic Malignancies

Six patients developed T-cell acute lymphoblastic leukemia (T-ALL) between 16 months and 5 y after GT, all of whom carried gammaretroviral insertion within or close to the LMO2 gene locus. One patient developed acute myeloid leukemia (AML) and LAM-PCR identified an insertion within the MDS1 gene locus. Insertion site kinetics prior to onset of leukemia were markedly diverse. Whereas all T-ALL patients had a polyclonal IS pattern without indications for a clonal outgrowth, the patient developing AML showed a slow increase of a MDS1 clone contribution over time. Of note, 2 patients with T-ALL developed AML shortly after or during maintenance therapy, with dominant clones harboring vector ISs close to either MDS1 or MN1 gene loci, respectively. In summary, we were able to demonstrate the feasibility of GT for WAS and the sustainability of WAS gene expression and functional correction over years, but also that classical gammaretroviral gene therapy is associated with an unacceptably high rate of secondary malignancies in WAS, raising considerable safety concerns.

“Self-inactivating” Vectors as a Novel Tool for Gene Therapy

Over the last years, significant improvements to viral vectors have been proposed and tested experimentally. One of the major advancements is probably the creation of so-called “self-inactivating” (SIN) viruses. By deleting enhancer elements in the LTR region and using internal mammalian promoters, the ability of SIN viruses to transactivate genomic loci in the proximity of the viral IS is dramatically reduced.29 In contrast to gammaretroviral vectors, lentiviral vectors are characterized by their ability to transduce non-dividing (stem) cells and a genomic integration pattern that does not favor the promoter-region of genes as much as gammaretroviruses do.30 However, choosing the right internal promoter can be difficult. While strong and ubiquitously active promoters may offer strong expression of the respective gene of interest, concerns have arisen about pathological effects of non-physiological gene expression in defined cellular lineages.31,32 This may not be a concern in WAS (WAS-protein is physiologically expressed in all nucleated haematopoietic cells and platelets), yet tissue-specific promoters, like the reconstituted physiological WAS promoter for the first SIN-lenti gene therapy trial for WAS,33 may promise more physiological lineage-specific gene expression. However, intrinsic promoters are not yet readily available for every gene of interest. In addition to using endogenous promoters, replacing VSV-G pseudotyping with a target-cell-specific
envelope might help to increase specificity and limit potential-side effects.34,35

Value of Insertion Site Monitoring to Predict Onset of Leukemia and for Treatment Decisions

In contrast to the first 2 patients enrolled in the Paris trial for yc-SCID,18,19 whose clones harboring LMO2 gene insertions increased slowly and steadily, IS monitoring could not predict the onset of the fast progressing T-ALL in our patients (regular follow-up analysis was undertaken at intervals of 3 to 6 months). A possible reason for the fast T-ALL progression may be a pre-leukemic clone expansion in a poorly accessible niche like the thymus or lymph nodes, and the acute release of those clones at the onset of leukemia. In contrast, for 2 of the AML patients, an increase of contribution of clones with insertions in close proximity to the MECOM gene locus had been detected months prior to onset of leukemia, suggesting a slow expansion of a (pre-)malignant clone. In general, integration site analysis is useful to identify integration clusters in certain gene loci, i.e. LMO2 and MECOM, to reveal whether in vivo clonal selection occurs, and whether proto-oncogenes or cell proliferating genes are involved. IS monitoring can help to predict the onset of AML and, depending on donor availability, an early bone marrow transplantation can be considered. Even though monitoring clearly did not help to predict the onset of T-ALL by particular clones, the degree of polyclonality and the pace of malignant transformation during treatment can be helpful for the assessment of the risk probability of future malignant transformation and facilitate the decision on the need for an eventual stem cell transplantation (again depending on donor availability).

Population Dynamics and Homeostatic Control—how Human Gene Therapy Trials Significantly Differ from Insertional Mutagenesis Observed in vitro

Both the activation of oncogenes and the functional inactivation of tumor-suppressors after viral insertion into the genome are known risk factors for tumor development, and, therefore, have always been a major concern and point of discussion during the development of human gene therapy trials.36,37 While one single insertional transactivation of an oncogene can, theoretically, be enough to facilitate cellular expansion, malignant transformation typically requires the occurrence of at least a second hit. Furthermore, biological filters may prevent a dominant clonal outgrowth – for example, the activation of strong oncogenes in otherwise normal cells can lead to oncogenic stress and the subsequent activation of tumor-suppressor pathways and cell cycle arrest or cell death.38 Noteworthy, natural killer (NK) cells, monocytes and certain subsets of T cells (all of which are less functional in severe WAS) have important roles in the physiological anti-tumor immune response.39 It has been shown that expression of functional WAS protein in a WASP-negative cell can reconstitute the proliferative defects.40 It is unclear, however, if unphysiologically high levels of transgene expression may render hematopoietic cells more prone to expansion, possibly without dominant mutagenesis, after vector insertion. The use of SIN retroviral vectors with weaker and physiologically active endogenous promoters may prevent this “overcorrection” and make cells less susceptible to undergo clonal dominance.

The first HSCT studies using gammaretroviral vectors have yielded ambiguous results. Ectopic expression of the common gamma chain in yc-SCID patients resulted in T-cell ALL in 5 out of 20 patients, whereas expression of adenosine deaminase in ADA-SCID patients has not led to leukemogenesis. All patients and parents were informed about a risk of leukemogenesis associated with integrational gene activation is very high. New vector designs incorporating self-inactivating LTR configurations and mammalian promoters may improve safety.33 Even though long-term observations on efficacy and safety are still pending, there is hope that the introduction of these features will reduce side effects while preserving therapeutic efficacy over many years. The development of novel genome-engineering tools may offer new therapeutic strategies for patients with WAS and other primary immunodeficiency disorders.

Disclosure of Potential Conflicts of Interest

No potential conflict of interest was disclosed.

References
1. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in wiskott-aldrich syndrome. Cell 1994; 78:635-44; PMID:8869912; http://dx.doi.org/10.1016/0092-8674(94)90528-2
2. Ochs HD, Filipovich AH, Veyes P, Cowan MJ, Kapoor N. Wiskott-aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol. Blood Marrow Transpl 2009; 15:84-90; PMID:19147084; http://dx.doi.org/10.1016/j.bbmt. 2008.10.007
3. Thresher AJ. WASp in immune-system organization and function. Nat Rev Immunol 2002; 2:635-46; PMID:12299132; http://dx.doi.org/10.1038/nri884
4. Bouma G, Burns SO, Thresher AJ. Wiskott-aldrich syndrome: immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation. Immunobiology 2009; 214:778-90.
5. Banerjee PP, Pandey R, Zheng R, Suhoski MM, Monaco-Shawyer L, Orange JS. Cdc42-interacting protein-4 functionally links actin and microtubule networks at the cytolytic NK cell immunological synapse. J Exp Med 2007; 204:2305-20; PMID:17785506; http://dx.doi.org/10.1084/jem.20061893
6. Imai K, Morio T, Zhu Y, Jin Y, Isho S, Kajiwara M, Yara J-I, Mizutani S, Ochs HD, Nonoyama S. Clinical course of patients with WASP gene mutations. Blood 2004; 103:456-64; PMID:12969986; http://dx.doi.org/10.1182/blood-2003-05-1480
7. Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs HD, Cant AJ, Thresher AJ, Cowan MJ, Albert MH, et al. Long-term outcome and lineage-specific chimerism in 194 patients with wiskott-aldrich syndrome treated by hematopoietic cell transplantation in the period 1988-2009: an international collaborative study. Blood 2011; 118:1675-84; PMID:21659547; http://dx.doi.org/10.1182/blood-2010-11-319376
8. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011; 12:316-28; PMID:21668099; http://dx.doi.org/10.1038/nrg2971
9. Fischer A, Hacein-Bey Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol 2010; 11:457-60; PMID:20485269; http://dx.doi.org/10.1038/nri0610-457
10. Ott MG, Schmidt M, Schwarzwaldet K, Stein S, Siler U, Koehl U, Glimm H, Kühlecke K, Schilt A, Kunkel H, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by
insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12:401-9; PMID: 16582916; http://dx.doi.org/10.1038/nm1393
11. Aui A. Correction of ADA-SCID by stem cell gene therapy combined with gammadelta T cell conditioning. Science 2002; 296:2410-3; PMID:12088448; http://dx.doi.org/10.1126/science.1070167
12. Cavazana-Calvo M, Hacein-Bey S, De Saint Basile G, Gross F, Yoon E, Nushbaum P, Selz F, Hue C, Certain S, Casanova JL, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288:669-72; PMID:10784449; http://dx.doi.org/10.1126/science.288.5466.669
13. Hacein-Bey Abina S, Le Deist F, Carlier F, Bourneaud C, Hue C, De Villaray J-P, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, et al. Sustained correction of X-Linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185-93; PMID:11691146; http://dx.doi.org/10.1056/NEJMoa021616
14. Dave UP. Gene therapy insertional mutagenesis. Insights. Science 2004; 303:333; PMID:14726584; http://dx.doi.org/10.1126/science.1091916
15. Hacein-Bey Abina S, Hauer J, Lim A, Picard C., Hauer J, Lim A, Picard C., et al. Correction of X-Linked chronic granulomatous disease. J Clin Invest 2010; 118:196-204; 1-4; PMID:20057388
16. Stein S, Ott MG, Schulze-Stasner S, Jauch A, Bur winkel B, Knuber A, Schmidt M, Krumm A, Schwabe J, Glimm H, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16:198-204; 1-4; PMID:20057388
17. Cavazana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yoon E, Nushbaum P, Selz F, Hue C, Certain S, Casanova JL, et al. Gene therapy for human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288:669-72; PMID:10784449; http://dx.doi.org/10.1126/science.288.5466.669
18. Hacein-Bey Abina S, von Kalle C, Schmidt M, Krämer A, Kurzke T, et al. Correction of X-Linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12:401-9; PMID: 16582916; http://dx.doi.org/10.1038/nm1393
19. Ott MG, Schmidt M, Schwarzwalder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schulz A, Kurzke T, et al. Correction of X-Linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12:401-9; PMID: 16582916; http://dx.doi.org/10.1038/nm1393
20. Stein S, Ott MG, Schulze-Stasner S, Jauch A, Bur winkel B, Knuber A, Schmidt M, Krämer A, Schwabe J, Glimm H, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16:196-204; 1-4; PMID:20057388
21. Braun CJ, Brezger K, Paruzynski A, Wizsel M, Schwarzner A, Rothe M, Modlich U, Beier R, Göhring G, Steinemann D, et al. Gene therapy for wiskott-aldrich syndrome–long-term efficacy and genotoxicity. Sci Transl Med 2014; 6:227ra33; PMID: 24622513; http://dx.doi.org/10.1126/scitranslmed.3007280
22. Thrasher AJ, Hacein-Bey Abina S, Gaspar HB, DOrze IA, Dewey RA, Bohm M, Nowrouzi A, Ball CR, Glimm H, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363:1918-27; PMID:21067383; http://dx.doi.org/10.1056/NEJMoa1001548
23. Modlich U, Navarro S, Zychlinski D, Maetzig T, Tschopp J, et al. Insertional mutagenesis and gammaretroviral vectors. Mol Ther 2009; 162:670-7; PMID:23826732; http://dx.doi.org/10.1038/mt.2009.103
24. Thrasher AJ, Hacein-Bey Abina S, Gaspar HB, Blanche S, Davies EG, Parlex K, Gilmore K, King D, Howe S, Sinclair J, et al. Failure of SCID-X1 gene therapy in older patients. Blood 2005; 105:4257-5; PMID:16037233; http://dx.doi.org/10.1182/blood-2004-12-4837
25. Schmidt M, Schwarzwalder K, Bartholomea C, Zoua M, Ball C, Pilz I, Braun S, Glimm H, von Kalle C. High-resolution insertion-site analysis by linear amplification with hybridization to endogenous probes. Nat Methods 2007; 4:1051-7; PMID:18049649; http://dx.doi.org/10.1038/nmeth1103
26. Ho PA, Alonso TA, Gerbing RB, Pollard J A, Hirsch B, Raimondi SC, Cooper T, Gamis AS, Meshinchi S, Anderson P, Martínez-Gómez R, et al. Correction of X-linked chronic granulomatous disease. Nat Med 2010; 16:1427-36; PMID:18578012; http://dx.doi.org/10.1038/nm.2008.128
27. Baum C, von Karle C, Staal FJT, Li Z, Felske B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams DA. Chance or necessity? insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004; 9:5-13; PMID:14741772; http://dx.doi.org/10.1016/j.ymthe.2003.10.013
28. Anderson WF. The best of times, the worst of times. Science 2000; 288:627-9; PMID:10799000; http://dx.doi.org/10.1126/science.288.5466.627
29. Haigis KM. A sweet-cordero, new insights into oncogenic stress. Nat Genet 2011; 43:177-8; PMID:21527195; http://dx.doi.org/10.1038/ng0311-177
30. Vivier E, Ugolini S, Blaise D, Chabannon C, Moretta L, Cossarizza A, Bossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev 2012; 12.
31. Dewey RA, Avedillo Díez J, Ballmaier M, Filipovich A, Greif J, Gungor T, Hapel C, Maschian A, Noynan F, Pannicke U, et al. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro. Exp Hematol 2006; 34:1161-9; PMID:16939809; http://dx.doi.org/10.1016/j.exphem.2006.04.021